PureTech News

PureTech Awarded up to $11.4 Million from U.S. Department of Defense to Advance LYT-300 (Oral Allopregnanolone) for Fragile X-associated Tremor/Ataxia Syndrome

PureTech Initiates Phase 2a Clinical Trial of LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders

Results of Annual General Meeting

PureTech Founded Entity Akili Releases EndeavorOTCTM Video Game Treatment to Improve Attention in Adults with ADHD

PureTech to Present at the Jefferies Healthcare Conference

PureTech Founded Entity Sonde Health Announces Respiratory Responsive Vocal Biomarker Tool Differentiates Patients with Respiratory Conditions from Healthy Individuals

PureTech Founded Entity Vedanta Biosciences Receives Fast Track Designation for VE303 and Presents Phase 2 Data at Digestive Disease Week

PureTech Founded Entity Akili Announces Adults with ADHD See Significant Improvements in Attention, ADHD Symptoms, and Quality of Life in Clinical Trial of Akili’s EndeavorRx® Video Game-Based Therapeutic

PureTech Announces Annual Results for Year Ended December 31, 2022

PureTech Founded Entity Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies